Co-prescription of Gastro-protectants in Hospitalized Patients: An Analysis of What We Do and What We Think We Do

Journal of Clinical Gastroenterology

Volumn 44, Issue 3, 2010, Pages e51-e56

  Doherty, Glen A ^a   Cannon, Mary D ^a   Lynch, Karen M ^a   Ayoubi, Karim Z ^a   Harewood, Gavin C ^a   Patchett, Stephen E ^a   Murray, Frank E ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Antiplatelet agent; Gastro intestinal hemorrhage; Gastro protection; Prevention; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CORTICOSTEROID; DIPYRIDAMOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TEACHING HOSPITAL; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; ASPIRIN; ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 77649323055     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181a9f43b     Document Type: Article

References (41)

1. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.
2. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-2224.
3. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-830.
4. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.
5. Johnsen SP, Sorensen HT, Mellemkjoer L, et al. Hospitalization for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost. 2001;86:563-568.
6. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834-839.
7. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731-1738.
8. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
9. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-786.
10. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20:1091-1097.
11. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507-515.
12. Ibanez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235-242.
13. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20舁mg Once Daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465-2473.
14. Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol Assess. 2006;10:3-4, 11-13, 1-183.
15. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890-2907.
16. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3.
17. Murthy SK, Kauldher S, Targownik LE. Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 2006;23:1365-1372.
18. Targownik LE, Al-Mamfud A. The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. Aliment Pharmacol Ther. 2006;23:743-749.
19. Taha AS, Angerson WJ, Prasad R, et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther. 2007;26:1171-1178.
20. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153:1089-1093.
21. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133:790-798.
22. Collaboration AT. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 20021;324:71-86.
23. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
24. Rey E, Elola-Olaso CM, Rodriguez-Artalejo F, et al. Use of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general population. Aliment Pharmacol Ther. 2006;24:1585-1592.
25. Sung JJ. Combining aspirin with antithrombotic agents. BMJ. 2006;333:712-713.
26. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19:1051-1061.
27. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
28. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
29. Masso Gonzalez EL, Garcia Rodriguez LA. Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther. 2008;28:629-637.
30. Saini SD, Schoenfeld P, Fendrick AM, et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med. 2008;168:1684-1690; discussion 1691.
31. Cullen G, Kelly E, Murray FE. Patients' knowledge of adverse reactions to current medications. Br J Clin Pharmacol. 2006;62:232-236.
32. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-34.
33. van Vliet EP, Otten HJ, Rudolphus A, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608-612.
34. Levy-Neumand O, Carniaux F, Bonaz B, et al. Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications. Gastroenterol Clin Biol. 2007;31:78-83.
35. Labenz J, Petersen KU, Rosch W, et al. A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2003;17:1015-1019.
36. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50:366-372.
37. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047-2056.
38. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960.
39. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950-955.
40. Harmark L, van der Wiel HE, de Groot MC, et al. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64:743-752.
41. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545-553.